Jakob Christensen

Jakob Christensen

Auto-generated profile, based on publicly available information

Jakob Christensen

Department of Clinical Medicine Aarhus University Aarhus Denmark

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2013 in JAMA
Verified
Journal Article
Open access
PDF file
JCJakob Christensen
Jakob Christensen
TGTherese Koops Grønborg
Therese Koops Grønborg
MSMerete Juul Sørensen
Merete Juul Sørensen
DSDiana Schendel
Diana Schendel
EPErik Thorlund Parner
Erik Thorlund Parner
MVMogens Vestergaard
Mogens Vestergaard
Antiepileptic drug exposure during pregnancy has been associated with an increased risk for congenital malformations and delayed cognitive development in the offspring,1-3 but little is known about the risk of other serious neuropsychiatric disorders. Autistic symptoms have been described in case series of children exposed in utero to valproic acid,4-7 and it has been suggested that valproate given to animals during pregnancy may constitute an experimental model of autism.8-10

1 June 2018 in The Lancet Neurology
Verified
Journal Article
Closed access
TTTorbjörn Tomson
Torbjörn Tomson
DBDina Battino
Dina Battino
EBErminio Bonizzoni
Erminio Bonizzoni
JCJohn Craig
John Craig
DLDick Lindhout
Dick Lindhout
MZMorteza Zarifi-Oskoie
Morteza Zarifi-Oskoie

1 August 2007 in The Lancet Neurology
Verified
Journal Article
Closed access
JCJakob Christensen
Jakob Christensen
MVMogens Vestergaard
Mogens Vestergaard
PMPreben Bo Mortensen
Preben Bo Mortensen
PSPer Sidenius
Per Sidenius
EAEsben Agerbo
Esben Agerbo

1 March 2009 in The Lancet
Verified
Journal Article
Closed access
JCJakob Christensen
Jakob Christensen
MPMarianne G Pedersen
Marianne G Pedersen
CPCarsten B Pedersen
Carsten B Pedersen
PSPer Sidenius
Per Sidenius
JOJørn Olsen
Jørn Olsen
MVMogens Vestergaard
Mogens Vestergaard

1 May 2018 in The Lancet Psychiatry
Verified
Journal Article
Closed access
JFJesse R Fann
Jesse R Fann
ARAnette Riisgaard Ribe
Anette Riisgaard Ribe
HPHenrik Schou Pedersen
Henrik Schou Pedersen
MFMorten Fenger-Grøn
Morten Fenger-Grøn
JCJakob Christensen
Jakob Christensen
MVMogens Vestergaard
Mogens Vestergaard

26 August 2003 in Neurology
Verified
Journal Article
Closed access
PDF file
SASabers Anne
Sabers Anne
IOInger Öhman
Inger Öhman
JCJakob Christensen
Jakob Christensen
TTTorbjörn Tomson
Torbjörn Tomson
The mean steady-state plasma concentration of lamotrigine (LTG) was 13 μmol/L in 22 women taking LTG in combination oral contraceptives (OC) compared with 28 μmol/L among 30 women on LTG who did not take OC (p < 0.0001). The LTG dose/body weight/plasma concentration was 2.1 L/kg/day in women on OC compared with 0.8 L/kg/day in women without OC (p < 0.0001), indicating that LTG plasma levels are reduced by >50% during OC co-medication. It is advisable to monitor LTG plasma levels in conjunction with initiation or withdrawal of OC in women on LTG therapy.